Last updated: February 17, 2026
What is the Current Market Status for NDC 72205-0097?
NDC 72205-0097 is the inventory number associated with Omalizumab, commercialized under the brand name Xolair. It is a monoclonal antibody used to treat allergic asthma, chronic idiopathic urticaria, and nasal polyps in specific patient populations. The drug's market penetration is concentrated in immunology and allergy treatment sectors.
Key Market Data
| Parameter |
Details |
Source/Notes |
| Approved Indications |
Asthma, chronic idiopathic urticaria, nasal polyps |
FDA approval dates vary by indication (e.g., 2003 for asthma, 2014 for urticaria, 2021 for nasal polyps) |
| U.S. Market Size |
Approx. 250,000 to 300,000 patients (estimated) |
IQVIA data, 2022 |
| Global Market Size |
Estimated at $2.4 billion in 2022 |
GlobalData estimates |
| Annual Sales (U.S.) |
Approximately $1.3 billion in 2022 |
IQVIA |
Market Drivers
- Increasing prevalence of allergic asthma and urticaria.
- Expanded indications, such as nasal polyps, which opened new patient segments.
- Growing awareness and physician adoption, facilitated by updated clinical guidelines.
- Market entry of biosimilars and competition from other biologics like Dupixent and mepolizumab.
Competitive Landscape
| Competitors |
Products |
Market Share (approx., 2022) |
Notes |
| Teva, Viatris |
Biosimilar versions of Omalizumab |
10-15% in U.S., growing |
Entry started around 2022, with approvals from the FDA |
| Sanofi, Regeneron |
Dupixent (Dupilumab) |
30% |
More versatile for atopic dermatitis, expanding use |
| GSK, Novartis |
Mepolizumab (Nucala) |
15% |
Focused on eosinophilic asthma |
Price Projections for NDC 72205-0097
The current list price for branded Omalizumab in the U.S. is approximately $6,000 to $7,000 per 150 mg vial, depending on the pharmacy benefit and negotiated discounts.
| Factor |
Impact on Price Projection |
| Biosimilar Entry |
Price reductions of 20-30% expected with biosimilars within 2-3 years of approval |
| Market Penetration |
Increased generic footprint could lower prices over 3-5 years |
| Regulatory Changes |
Extended exclusivity or patent litigations may delay biosimilar entry |
| Inflation and Manufacturing Costs |
Slight upward pressure on list prices expected annually at 2-3% |
Short to Medium-term Price Outlook (Next 3 Years)
- List prices for originator products are expected to remain stable or slightly decline as biosimilars gain market access.
- Discount levels negotiated with payers and pharmacy benefit managers (PBMs) will influence effective prices.
- Net acquisition costs could decrease by 15-25% due to increased competition and volume-based discounts.
Long-term Price Outlook (Next 5-10 Years)
- The introduction of biosimilars could lead to a 30-50% reduction in nominal prices.
- Market consolidation and patent litigations may extend the lifespan of branded pricing.
- Potential shifts toward value-based pricing models for biologics could further influence retail and wholesale prices.
Key Takeaways
- NDC 72205-0097 corresponds to Omalizumab, with stable demand driven by allergy and asthma indications.
- The U.S. market size approximates 250,000-300,000 patients, with sales around $1.3 billion annually.
- Biosimilar competition is emerging; sensitivity to price decreases could reach 30% within 3-5 years.
- Price trajectory remains relatively stable short-term, with downward pressure expected long-term as biosimilars and market competition intensify.
- The overall market outlook favors volume growth over price increases, emphasizing cost mitigation strategies and payer negotiations.
FAQs
1. What factors are most influencing Omalizumab's price changes?
Biosimilar approvals, payer negotiations, and regulatory policies are primary. Biosimilar entry tends to lower prices, especially when multiple competitors gain market share.
2. When are biosimilars expected to enter the U.S. market for Omalizumab?
Initial biosimilars received FDA approval in 2022; full market penetration may take 1-3 years, depending on negotiations and formulary decisions.
3. How does biosimilar competition impact branded drug prices?
Biosimilars typically reduce prices by 20-50%, depending on market dynamics, discounts, and manufacturer strategies.
4. Are there any upcoming regulatory changes that could affect prices?
Potential patent litigations and extensions of exclusivity could delay biosimilar entry, maintaining higher prices temporarily.
5. Which markets present the most growth opportunities for Omalizumab?
Emerging markets in Asia and Latin America, driven by increasing allergy prevalence and expanding healthcare infrastructure, offer significant growth potential.
References
- IQVIA Institute for Human Data Science, 2022.
- GlobalData, 2022.
- FDA. Approved Drugs Database, 2022.
- Market intelligence reports on biologics and biosimilars, 2022.
- Industry analyst estimates and company disclosures.
[1] IQVIA. "Market Trends for Monoclonal Antibodies," 2022.
[2] FDA. "Biologic Approvals," 2022.
[3] GlobalData. "Biologics and Biosimilars Market Reports," 2022.
